BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31308519)

  • 1. Structure of the full-length Clostridium difficile toxin B.
    Chen P; Lam KH; Liu Z; Mindlin FA; Chen B; Gutierrez CB; Huang L; Zhang Y; Hamza T; Feng H; Matsui T; Bowen ME; Perry K; Jin R
    Nat Struct Mol Biol; 2019 Aug; 26(8):712-719. PubMed ID: 31308519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
    Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
    J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a neutralizing antibody helps identify structural features critical for binding of
    Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
    J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
    [No Abstract]   [Full Text] [Related]  

  • 4. Four distinct structural domains in Clostridium difficile toxin B visualized using SAXS.
    Albesa-Jové D; Bertrand T; Carpenter EP; Swain GV; Lim J; Zhang J; Haire LF; Vasisht N; Braun V; Lange A; von Eichel-Streiber C; Svergun DI; Fairweather NF; Brown KA
    J Mol Biol; 2010 Mar; 396(5):1260-70. PubMed ID: 20070948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region.
    Larabee JL; Krumholz A; Hunt JJ; Lanis JM; Ballard JD
    J Biol Chem; 2015 Mar; 290(11):6975-85. PubMed ID: 25614625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic Toxin-Derived Peptides Destabilize and Inactivate
    Larabee JL; Bland SJ; Hunt JJ; Ballard JD
    mBio; 2017 May; 8(3):. PubMed ID: 28512094
    [No Abstract]   [Full Text] [Related]  

  • 7. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile.
    Murase T; Eugenio L; Schorr M; Hussack G; Tanha J; Kitova EN; Klassen JS; Ng KK
    J Biol Chem; 2014 Jan; 289(4):2331-43. PubMed ID: 24311789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neutralizing antibody that blocks delivery of the enzymatic cargo of
    Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
    J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure and conformational dynamics of
    Chen B; Basak S; Chen P; Zhang C; Perry K; Tian S; Yu C; Dong M; Huang L; Bowen ME; Jin R
    Life Sci Alliance; 2022 Jun; 5(6):. PubMed ID: 35292538
    [No Abstract]   [Full Text] [Related]  

  • 11. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
    Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
    PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of
    Raeisi H; Azimirad M; Asadzadeh Aghdaei H; Zarnani AH; Abdolalizadeh J; Yadegar A; Zali MR
    Microbiol Spectr; 2023 Sep; 11(5):e0531022. PubMed ID: 37668373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
    Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
    Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.
    Mansfield MJ; Tremblay BJ; Zeng J; Wei X; Hodgins H; Worley J; Bry L; Dong M; Doxey AC
    PLoS Pathog; 2020 Dec; 16(12):e1009181. PubMed ID: 33370413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional defects in
    Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
    J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
    [No Abstract]   [Full Text] [Related]  

  • 17. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile.
    Lanis JM; Barua S; Ballard JD
    PLoS Pathog; 2010 Aug; 6(8):e1001061. PubMed ID: 20808849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.